跳至主要内容
临床试验/NCT00052572
NCT00052572已完成2 期

A Multicenter Phase II Study Of BMS 247550 (Epothilone B Analogue) In Indolent Lymphoproliferative Disorders

Memorial Sloan Kettering Cancer Center3 个研究点 分布在 1 个国家目标入组 35 人开始时间: 2002年10月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
35
试验地点
3
主要终点
Safety

研究概览

简要总结

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of ixabepilone in treating patients who have relapsed or refractory lymphoproliferative disorders.

详细描述

OBJECTIVES:

Primary

  • Determine the frequency and duration of complete and partial response rates for patients with relapsed or refractory indolent lymphoproliferative disorders treated with ixabepilone.

Secondary

  • Determine the time to progression and overall survival of patients treated with this drug.
  • Determine the toxicity of this drug in these patients.

研究设计

研究类型
Interventional
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Safety

Efficacy

次要结局

  • Progression-free survival
  • Mean and median duration of response
  • Mean and median duration of progression-free and overall survival
  • Probability of polymerase chain reaction negativity after treatment

研究者

申办方类型
Other

研究点 (3)

Loading locations...

相似试验

Ixabepilone in Treating Patients With Relapsed or... | 临床试验